TY  - GEN
AU  - Ciruelos,Eva
AU  - Apellániz-Ruiz,María
AU  - Cantos,Blanca
AU  - Martinez-Jáñez,Noelia
AU  - Bueno-Muiño,Coralia
AU  - Echarri,Maria-Jose
AU  - Enrech,Santos
AU  - Guerra,Juan-Antonio
AU  - Manso,Luis
AU  - Pascual,Tomas
AU  - Dominguez,Cristina
AU  - Gonzalo,Juan-Francisco
AU  - Sanz,Juan-Luis
AU  - Rodriguez-Antona,Cristina
AU  - Sepúlveda,Juan-Manuel
TI  - A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer
SN  - 1549-490X
PY  - 2020///0701
KW  - Aged
KW  - Albumins
KW  - administration & dosage
KW  - Antineoplastic Agents, Phytogenic
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Female
KW  - Genetic Predisposition to Disease
KW  - Humans
KW  - Middle Aged
KW  - Paclitaxel
KW  - Polymorphism, Genetic
KW  - Polyneuropathies
KW  - chemically induced
KW  - Quality of Life
KW  - Receptor, ErbB-2
KW  - metabolism
KW  - Receptors, Eph Family
KW  - genetics
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1634/theoncologist.2017-0664
ER  -